Endocannabinoids in basal ganglia circuits: Implications for Parkinson disease

Neurology

Volumn 69, Issue 3, 2007, Pages 306-309

  Benarroch, Eduardo ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHYDONOIL GLYCEROL; 4 AMINOBUTYRIC ACID; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABIS; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; LEVODOPA; NABILONE; RIMONABANT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

BASAL GANGLION; BRADYKINESIA; BRAIN STEM; CALCIUM CELL LEVEL; CHEMICAL ANALYSIS; CLINICAL TRIAL; CORPUS STRIATUM; DEPOLARIZATION; DOPAMINERGIC SYSTEM; DRUG DOSE ESCALATION; DYSKINESIA; HUMAN; LOCOMOTION; MOTOR ACTIVITY; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECT; METABOLISM; NERVE CELL NETWORK; PHYSIOLOGY; PROTEIN BINDING;

ANIMALS; BASAL GANGLIA; ENDOCANNABINOIDS; HUMANS; NERVE NET; PARKINSON DISEASE; PROTEIN BINDING; RECEPTORS, CANNABINOID;

EID: 34547569805     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000267407.79757.75     Document Type: Article

References (23)

1. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462.
2. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002;296:678-682.
3. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003;4:873-884.
4. Brotchie JM. CB1 cannabinoid receptor signaling in Parkinson's disease. Curr Opin Pharmacol 2003;3:54-61.
5. van der Stelt M, Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 2003;480:133-150.
6. Fernandez-Ruiz J, Gonzales S. Cannabinoid control of motor function at the basal ganglia. Handb Exp Pharmacol 2005:479-507.
7. DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia (review). Arch Neurol 2007;64:20-24.
8. Engler B, Freiman I, Urbanski M, Szabo B. Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouse. J Pharmacol Exp Ther 2006;316:608-617.
9. Ronesi J, Gerdeman GL, Lovinger DM. Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. J Neurosci 2004;24:1673-1679.
10. Venderova K, Brown TM, Brotchie JM. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. Exp Neurol 2005;194:284-287.
11. Julian MD, Martin AB, Cuellar B, et al. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 2003;119:309-318.
12. de Lago E, de Miguel R, Lastres-Becker I, Ramos JA, Fernandez-Ruiz J. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res 2004;1007:152-159.
13. Maccarrone M, Gubellini P, Bari M, et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem 2003;85:1018-1025.
14. Lastres-Becker I, Cebeira M, de Ceballos ML, et al. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci 2001;14:1827-1832.
15. van der Stelt M, Fox SH, Hill M, et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned nonhuman primate models of Parkinson's disease. Faseb J 2005;19:1140-1142.
16. Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2002;17:1180-1187.
17. Melis M, Pillolla G, Bisogno T, et al. Protective activation of the endocannabinoid system during ischemia in dopaminergic neurons. Neurobiol Dis 2006;24:15-27.
18. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001;57:2108-2111.
19. Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63:1245-1250.
20. Venderova K, Ruzicka E, Vorisek V, Visnovsky P. Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms. Mov Disord 2004;19:1102-1106.
21. Mesnage V, Houeto JL, Bonnet AM, et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol 2004;27:108-110.
22. Fernandez-Espejo E, Caraballo I, de Fonseca FR, et al. Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis 2005;18:591-601.
23. Gonzalez S, Mena MA, Lastres-Becker I, et al. Cannabinoid CB (1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice. Brain Res 2005;1046:195-206.